Moderna, Inc. (MRNA): Price and Financial Metrics

Moderna, Inc. (MRNA): $118.25

0.18 (+0.15%)

POWR Rating

Component Grades













Add MRNA to Watchlist
Sign Up

Industry: Biotech



in industry


  • MRNA scores best on the Value dimension, with a Value rank ahead of 97.12% of US stocks.
  • MRNA's strongest trending metric is Growth; it's been moving down over the last 177 days.
  • MRNA's current lowest rank is in the Stability metric (where it is better than 3.28% of US stocks).

MRNA Stock Summary

  • MRNA has a market capitalization of $46,822,673,421 -- more than approximately 95.72% of US stocks.
  • Over the past twelve months, MRNA has reported earnings growth of 310.16%, putting it ahead of 94.63% of US stocks in our set.
  • Revenue growth over the past 12 months for MODERNA INC comes in at 227.58%, a number that bests 95.94% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to MODERNA INC, a group of peers worth examining would be MU, LRCX, GMAB, AMAT, and VRTX.
  • Visit MRNA's SEC page to see the company's official filings. To visit the company's web site, go to

MRNA Valuation Summary

  • MRNA's price/sales ratio is 2.1; this is 10.53% higher than that of the median Healthcare stock.
  • MRNA's EV/EBIT ratio has moved up 22.9 over the prior 46 months.

Below are key valuation metrics over time for MRNA.

Stock Date P/S P/B P/E EV/EBIT
MRNA 2022-09-23 2.1 2.7 3.4 3.0
MRNA 2022-09-22 2.1 2.7 3.5 3.0
MRNA 2022-09-21 2.1 2.7 3.5 3.0
MRNA 2022-09-20 2.2 2.8 3.6 3.1
MRNA 2022-09-19 2.2 2.8 3.6 3.1
MRNA 2022-09-16 2.3 3.0 3.8 3.3

MRNA's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • MRNA has a Quality Grade of A, ranking ahead of 98.11% of graded US stocks.
  • MRNA's asset turnover comes in at 0.829 -- ranking 29th of 682 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows MRNA's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.829 0.859 4.068
2021-06-30 0.688 0.865 4.248
2021-03-31 0.388 0.926 0.804
2020-12-31 0.183 0.990 -0.511
2020-09-30 0.084 1.000 -0.360
2020-06-30 0.048 1.000 -0.322

MRNA Price Target

For more insight on analysts targets of MRNA, see our MRNA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $286.15 Average Broker Recommendation 1.84 (Hold)

MRNA Stock Price Chart Interactive Chart >

Price chart for MRNA

MRNA Price/Volume Stats

Current price $118.25 52-week high $376.65
Prev. close $118.07 52-week low $115.03
Day low $118.08 Volume 3,856,000
Day high $122.58 Avg. volume 6,419,520
50-day MA $147.69 Dividend yield N/A
200-day MA $160.80 Market Cap 47.04B

Moderna, Inc. (MRNA) Company Bio

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Derrick J. Rose, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA

MRNA Latest News Stream

Event/Time News Detail
Loading, please wait...

MRNA Latest Social Stream

Loading social stream, please wait...

View Full MRNA Social Stream

Latest MRNA News From Around the Web

Below are the latest news stories about MODERNA INC that investors may wish to consider to help them evaluate MRNA as an investment opportunity.

Why Moderna Was a Sickly Stock Today

A shuffle at the top of the executive ranks, combined with the continued decline of the coronavirus, rattles some investors.

Yahoo | September 29, 2022

UPDATE 1-Around 3.2 mln Americans received updated COVID boosters last week -CDC

Around 3.2 million people in the United States received updated COVID-19 booster shots over the past week, the Centers for Disease Control and Prevention said on Thursday. The 7.6 million figure represents only 3.5% of the 215.5 million people in the United States aged 12 or older who are eligible to receive the shots because they have completed their primary vaccination series. The shots are being administered at a slower pace than last year, when the United States initially authorized COVID boosters just for older and immunocompromised people.

Yahoo | September 29, 2022

EMA Accepts Moderna's (MRNA) Filing for Omicron BA.4, BA.5 Booster

The EMA accepts Moderna's (MRNA) regulatory filing seeking authorization for bivalent COVID-19 booster vaccine, mRNA-1273.222, designed to target the Omicron BA.4 and BA.5 subvariants.

Yahoo | September 29, 2022

Pfizer (PFE), BNTX Seek EU Nod for Omicron Booster in Kids

Pfizer (PFE) and BioNTech seek to expand the EU label of their Omicron BA.4/BA.5-adapting bivalent COVID vaccine for children. It is already authorized for use in adolescents and adults.

Yahoo | September 29, 2022

These 2 Growth Stocks Have Fallen Out of Grace. Are They Buys?

In the past two years, biotech companies Moderna (NASDAQ: MRNA) and Novavax (NASDAQ: NVAX) rose to fame thanks to their successful attempts to develop vaccines for COVID-19 and help us end the outbreak. The pandemic isn't over yet, but Moderna and Novavax have given up substantial chunks of their value in the past year. Where does that leave Moderna and Novavax?

Yahoo | September 29, 2022

Read More 'MRNA' Stories Here

MRNA Price Returns

1-mo -14.66%
3-mo N/A
6-mo -27.03%
1-year -65.33%
3-year 684.67%
5-year N/A
YTD -53.44%
2021 143.11%
2020 434.10%
2019 28.09%
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.5023 seconds.